B2BROKER Launches cTrader Support & Maintenance Service
B2BROKER, a leading liquidity and technology provider, has expanded its services with a new cTrader support and maintenance solution, complementing its existing MT4 and MT5 service offerings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211557945/en/
B2BROKER, a multi-asset liquidity and technology provider, announces the release of its cTrader support and maintenance service. The cTrader Service offers setup, ongoing maintenance, and comprehensive support for your cTrader server, saving you time and financial resources. (Graphic: Business Wire)
cTrader is a widely used multi-asset FOREX/CFD trading platform. Over 300 brokers use it, and adoption is expected to reach 80%. However, high maintenance costs and lengthy team training—often taking up to six months—can pose challenges for brokers.
B2BROKER’s cTrader service solution provides comprehensive technical support and expert dealing training, enabling brokers to streamline operations, reduce costs, and focus on growth.
Notably, clients with an existing cTrader server can benefit from a comprehensive audit service, including a full review of current settings, optimisation recommendations, and seamless transition preparation for B2BROKER’s maintenance.
Here’s a breakdown of the core features included in B2BROKER’s cTrader service:
- Platform configurations
- Server support
- Settings control
- Trading conditions changes
- Symbol sessions modification
- Logs review
Why Choose B2BROKER’s cTrader Service?
B2BROKER’s cTrader service offers a superior alternative to in-house management, providing brokers with expert support, cost savings, and seamless operations.
With extensive expertise in configuring and customising cTrader, B2BROKER’s specialists ensure faster setup, optimised performance, and reduced training requirements—far exceeding the capabilities of most internal teams. This allows brokers to streamline operations without the burden of additional staffing.
The service is also highly cost-effective, offering a more affordable solution than maintaining a full-time in-house team. Clients benefit from 24/7 support and continuous monitoring, ensuring platform stability and peak performance at all times.
B2BROKER takes full responsibility for server infrastructure, employing proactive measures and automated solutions to maintain system reliability and swiftly resolve any issues, keeping trading operations smooth and uninterrupted.
Other benefits of choosing B2BROKER include:
- Team of Market Experts: B2BROKER’s team is continuously on track with the most recent cTrader updates and best practices.
- On-call Systems: Customised support levels with proactive tools that guarantee the quickest resolution to any issue.
- Risk Management Assistance: B2BROKER offers advanced systems for setting risk limits on trading accounts and provides tailored suggestions to every business needs.
- Direct Communication: Brokers can enjoy direct communication channels with cTrader managers to efficiently deal with all necessary liaisons.
- Extended Knowledge Base: Clients can access valuable resources for continuous learning and support, including Zendesk Knowledge Base and a dedicated YouTube channel.
- Training Services: B2BROKER’s team will train the client’s technicians in all aspects of platform customisation and remain available for consultations.
One Solution That Suits All Business Models
B2BROKER recognises that every trading business has unique requirements. Therefore, whether a broker operates independently with cTrader technology or as a standalone entity, B2BROKER offers flexible service plans tailored to diverse business models, ensuring optimised performance and expert support.
“We’ve been in the trading technology field for over a decade, growing alongside our partners at Spotware, the creators of cTrader. We were among the first to launch a cTrader white label solution, and we've recently added a cTrader prop trading white label solution to our offerings. I'm proud to say that our long-standing relationship with Spotware's excellent team enables us to guarantee outstanding service.
“Let us take care of everything—from the setup to the daily management of your cTrader servers—so you can focus on achieving your business goals with confidence.”
Arthur Azizov, CEO & Founder of B2BROKER
Start with B2BROKER’s Professional cTrader Service
Choosing B2BROKER’s cTrader maintenance offers professional service to the trading platform, allowing brokers to focus on core business activities and ensuring that all operations are managed by comprehensive support and advanced tools.
Learn more about B2BROKER’s cTrader server service here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250211557945/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Group Holdings Inc. Announces Fourth Quarter and Full Year 2024 Financial Results28.3.2025 12:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (NASDAQ: SBC, “SBC Medical” or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for -the three months ended December 31, 2024 and full year 2024. Fourth Quarter 2024 HighlightsTotal revenues were $44 million, representing a 29% year-over-year decrease. Gross profit was $34 million, representing a 22% year-over-year decrease. Income from operations was $5 million, representing an 80% year-over-year decrease. EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $21 million, representing a 22% year-over-year decrease. EBITDA margin1was 47% for the fourth quarter of 2024, compared to 43% for the fourth quarter of 2023. Net income attributable to SBC Medical Group was $7 million, representing a 54% year-over-year decrease. Earnings per share, which is defined as net inco
SINOVAC Announces New Board Member and Chairman of the Audit Committee28.3.2025 12:00:00 CET | Press release
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) has appointed Sven H. Borho, CFA, as director to the Board to fill in a vacancy created by a recent resignation. As a qualified audit committee financial expert under Nasdaq Rule 5605, Mr. Borho has also been elected as the Chair of the Audit Committee of the Board. Mr. Borho is a founder and Managing Partner of OrbiMed and has over 30 years of experience investing in the healthcare sector. OrbiMed is a leading healthcare investment firm with approximately $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds and royalty/credit funds. OrbiMed funds have been shareholders of SINOVAC since 2013 and currently hold over 2.7 million shares. Following this appo
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX1128.3.2025 11:00:00 CET | Press release
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for HLX11, an investigational biosimilar of Perjeta® (pertuzumab). Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer, and adjuvant treatment for certain HER2-positive early breast cancer, among other indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250328881021/en/ The submission was based on a multicenter, randomized, double-blind, parallel-controlled phase 3 clinical study (NCT05346224) aimed to compare the efficacy and safety of HLX11 with reference Perjeta® (pertuzumab) as a neoadjuvant therapy in patients with HER2-positive, HR-negative early-stage, o
European DataWarehouse is Awarded Data Provider of the Year for the Fifth Time28.3.2025 08:46:00 CET | Press release
European DataWarehouse (EDW) is pleased to announce it was named Data Provider of the Year at the 2025 GlobalCapital European Securitization Awards in London. The award ceremony recognises the outstanding achievements in European structured finance and winners are selected by popular vote from industry participants. As defined by GlobalCapital, the program celebrates “the very best in the market, as chosen by the market”. This is the fifth time that EDW has won the prestigious Data Provider of the Year award, having also been awarded the honour in 2019, 2022, 2023 and 2024! Dr. Christian Thun, CEO of EDW, stated: “Receiving this award for the fifth time is a testament to the trust and recognition our team has earned within the European securitisation market. This achievement highlights our ongoing commitment to excellence and industry leadership.” Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “EDW continues to stand as a trusted partner in the securitisation mark
W. R. Berkley Corporation Confirms Mitsui Sumitomo Insurance Co. Intends to Purchase 15% of the Company’s Shares in Open Market or Private Transactions From Third Parties28.3.2025 07:48:00 CET | Press release
MSI also entered into a voting arrangement with a company that is owned by the Berkley family and trusts for their benefit, which holds approximately 16% of the Company’s outstanding Common Stock W. R. Berkley Corporation (NYSE: WRB) (the “Company”) today confirmed that Mitsui Sumitomo Insurance Co., Ltd. (“MSI”), a leading Japanese property and casualty insurance carrier, has entered into an arrangement (the “Investment and Voting Arrangement”) with a company owned by members of the Berkley family and trusts for their benefit (collectively, the “Berkley Family”) providing for MSI to purchase 15% of the Company’s outstanding common stock (the “Common Stock”) through open market purchases or private transactions with third parties. The Berkley Family will not be selling any of its Common Stock to MSI, nor will MSI be purchasing any shares from the Company as part of the arrangement. Under the terms of the agreements being entered into between MSI and the Berkley Family, once MSI acquire
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom